Search This Blog

Monday, June 13, 2016

BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

First Immunotherapy to Demonstrate Overall Survival Benefit Compared to Standard of Care in This Difficult-to-Treat Patient Population
Results Presented at EHA Presidential Symposium and Recognized as Top Abstract


Amgen - Investors - RSS Content
Posted by at
Labels:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)